
Quarterly report 2023-Q3
added 11-07-2023
Eargo Financial Ratios 2011-2026 | EAR
Annual Financial Ratios Eargo
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.1 | -0.1 | -0.4 | - | - | - | - | - | - | - | - | - |
P/S |
0.5 | 0.3 | 0.3 | - | - | - | - | - | - | - | - | - |
EPS |
-39.7 | -81.1 | -76.1 | -173.5 | -149.7 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
-53 M | -9.63 M | -156 M | 183 M | 172 M | - | - | - | - | - | - | - |
EBITDA per Share |
-26.8 | -78.4 | -82 | - | - | - | - | - | - | - | - | - |
EV/EBITDA |
-1.1 | -51.2 | - | - | - | - | - | - | - | - | - | |
PEG |
- | -4.66 | - | - | - | - | - | - | - | - | - | |
P/B |
0.2 | 0.1 | 0.1 | - | - | - | - | - | - | - | - | - |
P/CF |
-0.1 | -0.1 | -0.7 | - | - | - | - | - | - | - | - | - |
ROE % |
-156.15 | -228.09 | -20.55 | - | - | - | - | - | - | - | - | - |
ROA % |
-119.24 | -98.53 | -17.13 | - | - | - | - | - | - | - | - | - |
ROCE % |
-110.81 | -226.57 | -17.98 | - | - | - | - | - | - | - | - | - |
Current Ratio |
4.2 | 1.8 | 6.0 | - | - | - | - | - | - | - | - | - |
DSO |
70.8 | 92.8 | 10.0 | - | - | - | - | - | - | - | - | - |
DIO |
85.3 | 55.2 | 22.9 | - | - | - | - | - | - | - | - | - |
DPO |
123.5 | 98.4 | 50.2 | - | - | - | - | - | - | - | - | - |
Operating Cycle |
156.2 | 148.0 | 32.9 | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
32.7 | 49.6 | -17.4 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Eargo
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.83 | -1.21 | -1.06 | - | -25.7 | -16.48 | -15.59 | - | -2.02 | -0.5 | -0.36 | - | -57.73 | -23.66 | -43.76 | - | -46.26 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.86 | -1.24 | -1.04 | - | -13.1 | -15.9 | -14.7 | - | -1.98 | -0.47 | -0.33 | - | -17.4 | -17.9 | -41.6 | - | -44.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
32.31 | 210.08 | -36.42 | -222.89 | -300.22 | -516.92 | -239.36 | -95.64 | -100.65 | -28.34 | -20.76 | -14.47 | -6.68 | 6.12 | 16.95 | 22.77 | 22.77 | 14.98 | 7.55 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-116.15 | -134.73 | -127.63 | -87.67 | -127.15 | -123.20 | -110.54 | -54.53 | -58.71 | -23.41 | -17.28 | -12.06 | -56.58 | -96.93 | -94.09 | -44.52 | -44.52 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-38.89 | 72.59 | -163.91 | -281.04 | -358.10 | -506.87 | -238.06 | -95.09 | -99.03 | -25.91 | -17.95 | -12.86 | -5.15 | 6.51 | 9.38 | 7.72 | 7.72 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
2.8 | 3.2 | 3.6 | 4.2 | 0.8 | 1.1 | 1.4 | 1.8 | 2.0 | 5.4 | 5.9 | 6.0 | 6.0 | 6.0 | 6.0 | 0.9 | 0.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
10.9 | 16.2 | 14.8 | - | 77.3 | 154.2 | 123.3 | - | - | 41.3 | 18.9 | - | 19.0 | 21.7 | 21.1 | - | 12.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
112.9 | 71.8 | 67.3 | - | 89.4 | 121.5 | 95.5 | - | 57.2 | 40.0 | 37.7 | - | 46.0 | 48.0 | 55.1 | - | 36.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
101.7 | 89.5 | 105.6 | - | 112.2 | 196.7 | 175.2 | - | 107.3 | 94.4 | 91.5 | - | 101.1 | 105.5 | 112.2 | - | 69.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
123.8 | 88.0 | 82.1 | - | 166.7 | 275.7 | 218.9 | - | 57.2 | 81.3 | 56.6 | - | 65.0 | 69.8 | 76.1 | - | 48.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
22.1 | -1.5 | -23.4 | - | 54.5 | 79.1 | 43.7 | - | -50.1 | -13.1 | -34.9 | - | -36.1 | -35.8 | -36.1 | - | -20.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Eargo, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Butterfly Network
BFLY
|
$ 4.22 | 0.84 % | $ 893 M | ||
|
Delcath Systems
DCTH
|
$ 8.94 | -1.81 % | $ 320 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
- | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | ||
|
Lianluo Smart Limited
LLIT
|
- | 24.59 % | $ 44.8 M | ||
|
FONAR Corporation
FONR
|
$ 18.34 | 0.01 % | $ 120 M | ||
|
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
- | -5.86 % | $ 30.6 M | ||
|
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | ||
|
Inogen
INGN
|
$ 6.32 | -2.02 % | $ 168 M | ||
|
IRadimed Corporation
IRMD
|
$ 99.22 | 0.02 % | $ 1.26 B | ||
|
LivaNova PLC
LIVN
|
$ 63.34 | 0.16 % | $ 3.46 B | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
LENSAR
LNSR
|
$ 5.71 | -5.93 % | $ 65.8 M | ||
|
Medtronic PLC
MDT
|
$ 86.81 | -0.41 % | $ 112 B | ||
|
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | ||
|
IRIDEX Corporation
IRIX
|
$ 1.35 | -0.04 % | $ 21.8 M | ||
|
Apollo Endosurgery
APEN
|
- | - | $ 475 M | ||
|
Avinger
AVGR
|
- | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
- | -4.14 % | $ 702 M | ||
|
CHF Solutions, Inc.
CHFS
|
- | 1.15 % | $ 34.5 M | ||
|
Insulet Corporation
PODD
|
$ 225.4 | -0.74 % | $ 15.9 B | ||
|
AxoGen
AXGN
|
$ 32.32 | 1.8 % | $ 1.49 B | ||
|
Profound Medical Corp.
PROF
|
$ 5.16 | -4.36 % | $ 180 M | ||
|
CONMED Corporation
CNMD
|
$ 36.49 | -0.37 % | $ 1.13 B | ||
|
Orthofix Medical
OFIX
|
$ 11.76 | -0.93 % | $ 466 M | ||
|
Quanterix Corporation
QTRX
|
$ 3.66 | -7.23 % | $ 156 M | ||
|
Soliton, Inc.
SOLY
|
- | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
- | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
- | 0.03 % | $ 1.58 B | ||
|
Electromed
ELMD
|
$ 24.64 | 0.61 % | $ 208 M | ||
|
Misonix, Inc.
MSON
|
- | - | $ 462 M | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
Sintx Technologies
SINT
|
$ 2.58 | 1.12 % | $ 7.16 M | ||
|
Intersect ENT, Inc.
XENT
|
- | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
$ 0.72 | 6.28 % | $ 39.2 M | ||
|
Aethlon Medical
AEMD
|
$ 2.15 | -6.52 % | $ 3.36 M | ||
|
Sensus Healthcare
SRTS
|
$ 4.0 | -2.68 % | $ 65.3 M | ||
|
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | ||
|
Stryker Corporation
SYK
|
$ 328.28 | -1.3 % | $ 125 B | ||
|
Tactile Systems Technology
TCMD
|
$ 26.48 | -0.13 % | $ 606 M | ||
|
AdaptHealth Corp.
AHCO
|
$ 11.25 | 8.49 % | $ 1.52 B | ||
|
Myomo
MYO
|
$ 0.69 | -2.14 % | $ 28.9 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
$ 2.34 | -4.1 % | $ 137 M | ||
|
Invacare Corporation
IVC
|
- | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
$ 3.85 | 3.08 % | $ 144 M | ||
|
OrthoPediatrics Corp.
KIDS
|
$ 15.9 | -3.46 % | $ 373 M | ||
|
Penumbra
PEN
|
$ 334.59 | -0.29 % | $ 13 B |